SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY

Silvio Danese  1     Jean-Frédéric Colombel  2     Steve Hanauer  3     William J. Sandborn  4     Bruce E. Sands  2     Stefan Schreiber  5     Sang Joon Lee  6     Sung Hyun Kim  6     Yun Ju Bae  6     Sun Hee Lee  6     Seul Gi Lee  6     JoonHo Lee  6     Jong Min Kim  6     SIYOUNG YANG  6     Jimin Lee  6     Gahee Park  6     Juhyun Lee  6    
1 IRCCS San Raffaele Scientific Institute, Milan, Italy
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Northwestern University/ Feinberg School of Medicine, Chicago, IL, United States
4 University of California San Diego, La Jolla, United States
5 University Hospital Schleswig-Holstein, Kiel, Germany
6 Celltrion, Inc, Incheon, Korea, Republic of

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing